Influenza M2 Peptide Cell Penetration Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell-penetrating peptides have low efficiency in penetrating cells and limited types of cells they can penetrate, restricting the delivery of therapeutic molecules to their targets inside cells.
Innovation Solution
Development of polypeptides derived from the influenza virus M2 protein, specifically the sequence of amino acids 44-67, and their modified variants, which exhibit higher penetrating efficiency and can enter various cell types at low concentrations, facilitating the delivery of molecular cargoes into cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing cell-penetrating peptides are used, then cell penetration function is provided, but penetrating efficiency is low and cell types are limited
Solution Approach 1:
The patent modifies the amino acid sequence parameters of the M2 protein-derived peptide, specifically optimizing the hydrophobic helical region (amino acids 44-67) to enhance membrane interaction. This parameter optimization results in significantly improved penetrating efficiency across multiple cell types including HEK293, HeLa, and A549 cells, resolving the contradiction between penetration efficiency and cell type adaptability
Solution Approach 2:
The invention creates a composite peptide structure by combining the hydrophobic helical region of M2 protein (amino acids 44-67) with specific amino acid modifications to form a chimeric cell-penetrating peptide. This composite structure integrates the membrane-interacting properties of the viral protein with optimized sequences for enhanced cellular uptake across diverse cell types
2Productivity
If existing cell-penetrating peptides are used, then therapeutic molecule delivery is attempted, but delivery efficiency is insufficient
Solution Approach 1:
The patent optimizes the concentration parameter by demonstrating that the modified M2-derived peptide achieves effective therapeutic molecule delivery at lower concentrations compared to existing CPPs. The optimized amino acid sequence in the hydrophobic helical region enhances binding affinity to cell membranes, reducing the required peptide concentration while improving delivery efficiency of therapeutic molecules into cells
Data Source
AI summary
Provided are a cell-penetrating peptide based on influenza virus M2 protein and a method for preparing and transforming same. Further provided are a conjugate containing the cell-penetrating peptide, a fusion protein and a composition, wherein the cell-penetrating peptide can be used for penetrating cells, introducing a molecule into cells and treating diseases.